Search Results - "Pericleous, L"

The current economic burden of illness of osteoporosis in Canada by Hopkins, R. B., Burke, N., Von Keyserlingk, C., Leslie, W. D., Morin, S. N., Adachi, J. D., Papaioannou, A., Bessette, L., Brown, J. P., Pericleous, L., Tarride, J.

“…Summary We estimate the current burden of illness of osteoporosis in Canada is double ($4.6 billion) our previous estimates ($2.3 billion) due to improved data…”
Get full text

The burden and management of FXIII deficiency by de Jager, T., Pericleous, L., Kokot-Kierepa, M., Naderi, M., Karimi, M.

“…Summary Factor XIII congenital deficiency (FXIII CD) is a serious bleeding disorder resulting in a lifelong bleeding tendency, defective wound healing and…”
Get full text

Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada by DiBenedetti, D. B., Coles, T. M., Sharma, T., Pericleous, L., Kulkarni, R.

“…Summary Haemophilia A is a rare inherited bleeding disorder characterized by an inability of the blood to clot normally. Patients can experience spontaneous or…”
Get full text

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study by Lorigan, P., Marples, M., Harries, M., Wagstaff, J., Dalgleish, A.G., Osborne, R., Maraveyas, A., Nicholson, S., Davidson, N., Wang, Q., Pericleous, L., Bapat, U., Middleton, M.R.

“…Summary Background Advanced melanoma is an aggressive disease with a poor prognosis. Approved therapy is limited in the U.K. and, until recently, no treatment…”
Get full text

Payer Assessment and Reimbursement Policy for Rare Diseases: A Review of the Literature by Hutchings, A, Palaska, C, Schey, C, Pericleous, L, Petersen, J

Get full text

PMS31 Cost-Effectiveness of Abatacept for the Treatment of Rheumatoid Arthritis (RA) After the Failure of a First TNF inhibitor in the United Kingdom by Pericleous, L, Lebmeier, M

Get full text

Web-based study of patients and caregivers in the United States and Canada: Perspectives on improvements in stability of factor VIII products for hemophilia A by DiBenedetti, D.B, Coles, T.M, Ling, C, Sharma, T, Pericleous, L

Get full text

Associations between inhibitors, treatment regimen, and bleed frequency and health care practitioner utilisation in the haemophilia treatment centre (HTC): Global results from the haemophilia experiences, results and opportunities (HERO) study by Nugent, D, Stain, A.M, Gregory, M, Pericleous, L, Cooper, D.L, Iorio, A

Get full text

P.7.e.002 The cost-effectiveness of aripiprazole in the management of adolescent schizophrenia in the United Kingdom by Pericleous, L, Elliott, J, McAllister, R, Bentley, A, Harrison, L

Get full text

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1 by Pericleous, L M, Richards, J, Epenetos, A A, Courtenay-Luck, N, Deonarain, M P

“…The humanised HMFG-1 immunoglobulin has been extensively developed as a clinical immunotherapeutic agent for MUC1 expressing tumours. We have constructed a…”
Get full text

P.7.c.010 The cost effectiveness of aripiprazole for the treatment of adolescents with schizophrenia by Pericleous, L, Dudley, E, Lebmeier, M, Bentley, A, McAllister, R

Get full text

PSU15 the Economic Burden of Post-Transplant Events in Renal Transplant Patients in UK, Italy, Netherlands, Poland and Belgium by Sennfalt, K, Ling, C, Pericleous, L, Sbarigia, U, Gatta, F, Kolasa, K, Zagorska, A, Chamberlain, G, Pandit, P

Get full text

PMS79 Mixed Treatment Comparison of Biologic Agents in Patients with Rheumatoid Arthritis Who Have responded Inadequately to Methotrexate Therapy in the United Kingdom by Lebmeier, M, Pericleous, L, Taylor, P.C, Christensen, R, Drost, P, Bergman, G, Eijgelshoven, I, Guyot, P

Get full text

POSA282 Oncology Drugs without Phase III Data: Comparison of Reimbursement Recommendations Issued by the Canadian Agency for Drugs and Technologies in Health (CADTH), and the National Institute for Health and Care Excellence (NICE) by Singh, S, Hachborn, G, Jarrett, K, Pericleous, L, Benyo, S, Maoloni, M

Get full text

Differences in lipid treatment patterns in women versus men in a large cohort of patients with atherosclerotic cardiovascular disease in Ontario, Canada by Fairbairn, M, Goeree, R, Goodman, S.G, Rogoza, R.M, Packalen, M, Motsepe-Ditshego, P, Pericleous, L, Oh, P

Get full text

Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada by Fairbairn, M, Oh, P, Goeree, R, Rogoza, R.M, Packalen, M, Pericleous, L, Motsepe-Ditshego, P, Colgan, S, Goodman, S.G

Get full text

PCN210 Estimating the IMPACT of Delayed Access to Oncology Drugs on Patient Outcomes in Canada by Vanderpuye-Orgle, J., Erim, D., Maruszczak, M., Qian, Y., Lemay, J., Shah, A., Pericleous, L., Behboodi, A., Brenner, D.R.

Get full text

PATTERNS OF LOW-DENSITY LIPOPROTEIN CHOLESTOEROL MANAGEMENT AND GOAL ATTAINMENT IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 65 YEARS AND OLDER FROM ALBERTA AND ONTARIO by Rogoza, R., Oh, P., Goeree, R., Goodman, S., Fairbairn, M., Mackinnon, E., Pericleous, L., Motsepe-Ditshego, P., Anderson, T.

Get full text

PCV32 ECONOMIC BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND SPECIFIC EVENTS IN ONTARIO, CANADA by Rogoza, R., Oh, P., Goodman, S.G., Fairbairn, M., Packalen, M., Motsepe-Ditshego, P., Pericleous, L., Goeree, R.

Get full text

PCV57 - Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review by Ball, G, Campbell, K, Burke, N, Pericleous, L, Tarride, J

Get full text